A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma

Status:
Active, not recruiting

Trial end date:
2023-09-01

Target enrollment:

Participant gender:

This is a first in human phase 1 multicenter open label study in subjects with relapsed or refractory multiple myeloma.

Phase 1

Amgen